Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Market Cap
$3.02B
P/E Ratio
-8.33
1Y Stock Return
182.40%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
4.3
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RNA | 45.48% | $5.16B | +638.05% | 0.00% |
PTCT | 42.33% | $3.04B | +80.14% | 0.00% |
QS | 38.77% | $2.54B | -13.31% | 0.00% |
ENTA | 38.19% | $199.60M | -5.52% | 0.00% |
WIX | 36.95% | $10.24B | +90.29% | 0.00% |
KYMR | 36.04% | $2.77B | +125.95% | 0.00% |
CATX | 35.28% | $458.24M | +162.59% | 0.00% |
RYTM | 34.77% | $3.69B | +79.50% | 0.00% |
CRNX | 33.72% | $5.12B | +84.27% | 0.00% |
CPRX | 33.36% | $2.55B | +55.68% | 0.00% |
GSL | 33.28% | $832.14M | +32.08% | 6.32% |
MRSN | 33.24% | $274.24M | +40.51% | 0.00% |
NVCR | 33.19% | $1.78B | +34.75% | 0.00% |
KROS | 32.61% | $2.17B | +73.87% | 0.00% |
RXRX | 32.60% | $1.80B | -4.13% | 0.00% |
PLRX | 31.32% | $778.32M | -9.55% | 0.00% |
AZZ | 31.31% | $2.60B | +78.85% | 0.78% |
AXSM | 31.28% | $4.63B | +61.30% | 0.00% |
CVCO | 31.15% | $3.82B | +69.11% | 0.00% |
SNDX | 30.97% | $1.35B | +2.87% | 0.00% |
Current Value
$29.471 Year Return
Current Value
$29.471 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TRGP | 0.02% | $44.39B | +132.49% | 1.34% |
GPRK | 0.06% | $440.00M | -9.95% | 6.37% |
ARMK | -0.10% | $9.93B | +35.19% | 1.01% |
CASI | 0.12% | $71.56M | -6.32% | 0.00% |
ASUR | 0.21% | $233.14M | +12.13% | 0.00% |
RAMP | -0.22% | $1.86B | -16.17% | 0.00% |
THG | -0.24% | $5.88B | +36.24% | 2.08% |
HIHO | -0.26% | $8.63M | 0.00% | 6.12% |
SCWX | 0.26% | $743.12M | +40.27% | 0.00% |
VRSN | 0.30% | $17.13B | -16.16% | 0.00% |
LRN | 0.34% | $4.43B | +74.97% | 0.00% |
HSY | 0.37% | $34.45B | -10.68% | 3.21% |
XEL | -0.37% | $41.42B | +15.91% | 3.12% |
COCO | 0.38% | $2.01B | +24.49% | 0.00% |
PULM | -0.39% | $19.83M | +202.98% | 0.00% |
SRRK | 0.39% | $2.61B | +134.91% | 0.00% |
CMG | -0.40% | $80.02B | +33.62% | 0.00% |
WM | -0.41% | $87.92B | +27.58% | 1.34% |
EXC | 0.41% | $39.29B | +0.57% | 3.88% |
SCKT | -0.48% | $10.88M | +15.32% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SOC | -26.44% | $1.93B | +74.70% | 0.00% |
CBOE | -19.18% | $21.46B | +15.84% | 1.11% |
PEP | -14.51% | $215.02B | -6.60% | 3.35% |
LMT | -14.31% | $126.40B | +18.99% | 2.36% |
NOC | -13.29% | $71.54B | +4.23% | 1.60% |
OPK | -12.09% | $1.11B | +7.64% | 0.00% |
MCK | -11.57% | $78.15B | +35.51% | 0.42% |
SE | -9.30% | $60.12B | +197.12% | 0.00% |
UUU | -9.27% | $4.97M | -41.89% | 0.00% |
COR | -9.20% | $47.48B | +21.20% | 0.86% |
WTW | -8.75% | $30.98B | +26.60% | 1.13% |
CHD | -8.57% | $27.18B | +19.50% | 1.03% |
KVUE | -8.53% | $45.42B | +19.05% | 3.43% |
CI | -8.52% | $89.70B | +12.57% | 1.68% |
MOH | -8.48% | $16.16B | -21.56% | 0.00% |
TPST | -8.39% | $37.75M | -77.59% | 0.00% |
PGR | -8.10% | $149.10B | +57.29% | 0.45% |
TCTM | -7.87% | $8.10M | -42.99% | 0.00% |
CB | -7.87% | $114.43B | +26.00% | 1.24% |
PG | -7.49% | $402.15B | +14.14% | 2.33% |
Finnhub
Building the World's Leading Muscle Disease Company COMPANY OVERVIEW | NOVEMBER 2024 ...
Yahoo
- IND Application for DYNE-101 for DM1 Cleared by FDA - - New Clinical Data from DYNE-101 ACHIEVE Trial Expected in Early January 2025 - - Enrolling Registrational Cohort of DYNE-251 DELIVER Trial in DMD - WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third qua
SeekingAlpha
Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy opportunity. Learn more on DYN stock here.
Finnhub
WALTHAM, Mass., Nov. 07, 2024 -- Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically...
Finnhub
NEW YORK, Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. . Such investors are advised to contact Danielle Peyton...
Finnhub
WALTHAM - Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today...
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -26.27% | $388.04M | 1.43% |
VIXY | -25.44% | $195.31M | 0.85% |
TAIL | -14.21% | $67.98M | 0.59% |
USDU | -7.50% | $201.97M | 0.5% |
UUP | -6.79% | $309.25M | 0.77% |
SOYB | -6.68% | $27.32M | 0.22% |
SEIX | -5.75% | $268.81M | 0.62% |
SGOV | -5.15% | $27.53B | 0.09% |
XBIL | -5.07% | $637.70M | 0.15% |
FLTR | -4.76% | $1.79B | 0.14% |
TBIL | -4.64% | $4.38B | 0.15% |
KMLM | -4.42% | $353.87M | 0.9% |
CTA | -4.18% | $350.27M | 0.78% |
HTAB | -4.17% | $437.10M | 0.4% |
FLRN | -4.12% | $2.33B | 0.15% |
TPMN | -3.98% | $40.60M | 0.65% |
IBMM | -3.94% | $391.28M | 0.18% |
KRBN | -3.94% | $242.47M | 0.85% |
GOVZ | -3.86% | $313.00M | 0.1% |
EQLS | -3.76% | $76.08M | 1% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CORN | 0.01% | $61.12M | 0.2% |
MINT | 0.02% | $11.62B | 0.35% |
CANE | 0.13% | $17.72M | 0.29% |
DUSB | 0.16% | $797.63M | 0.15% |
JBBB | 0.27% | $1.26B | 0.49% |
FTXG | 1.17% | $30.81M | 0.6% |
DBA | 1.18% | $755.88M | 0.93% |
FMF | 1.28% | $244.61M | 0.95% |
DFSD | 1.53% | $3.63B | 0.16% |
CLOI | 1.67% | $715.40M | 0.4% |
XHLF | -2.04% | $874.27M | 0.03% |
HDRO | -2.06% | $164.26M | 0.3% |
GBIL | 2.32% | $5.60B | 0.12% |
IYK | -2.35% | $1.30B | 0.4% |
JUCY | 2.94% | $324.29M | 0.6% |
BILZ | 3.20% | $563.02M | 0.14% |
IAK | 3.25% | $760.79M | 0.39% |
XLP | 3.49% | $16.03B | 0.09% |
UCON | 3.64% | $3.19B | 0.85% |
KCCA | -3.64% | $220.51M | 0.87% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PTH | 45.45% | $143.31M | 0.6% |
XBI | 41.52% | $6.58B | 0.35% |
EFAA | 37.38% | $117.38M | 0% |
QQA | 37.03% | $135.01M | 0% |
ISRA | 36.92% | $79.78M | 0.59% |
XPH | 36.80% | $157.87M | 0.35% |
QQQJ | 36.77% | $698.04M | 0.15% |
CLOU | 36.69% | $349.39M | 0.68% |
IBB | 36.62% | $6.66B | 0.45% |
RSPA | 36.51% | $273.87M | 0% |
PBE | 36.30% | $258.53M | 0.58% |
SMLF | 36.06% | $1.44B | 0.15% |
ROBO | 35.69% | $1.05B | 0.95% |
FBT | 35.07% | $1.11B | 0.56% |
IWO | 34.67% | $12.56B | 0.24% |
CALF | 34.67% | $8.93B | 0.59% |
PRFZ | 34.55% | $2.65B | 0.39% |
GNOM | 34.35% | $70.59M | 0.5% |
TMSL | 33.80% | $288.12M | 0.55% |
ITEQ | 33.49% | $84.84M | 0.75% |